KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure by 媛뺤꽍誘�
22https://e-kcj.org
ABSTRACT
The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, 
the continuous progress and widespread adoption of screening and diagnostic strategies 
have led to an increase in the detection rate of HF, effectively increasing the number of 
patients requiring monitoring and treatment. Because HF is associated with substantial rates 
of mortality and morbidity, as well as high socioeconomic burden, there is an increasing 
need for developing specific guidelines for HF management. The Korean guidelines for the 
diagnosis and management of chronic HF were introduced in March 2016. However, chronic 
and acute HF represent distinct disease entities. Here, we introduce the Korean guidelines 
for the management of acute HF with reduced or preserved ejection fraction. Part II of this 
guideline covers the treatment of acute HF.
Keywords: Heart failure; Guideline; Treatment
Korean Circ J. 2019 Jan;49(1):22-45
https://doi.org/10.4070/kcj.2018.0349
pISSN 1738-5520·eISSN 1738-5555
Review Article
Received: Oct 4, 2018
Revised: Oct 14, 2018
Accepted: Dec 18, 2018
Correspondence to
Byung Su Yoo, MD
Division of Cardiology, Department of 
Medicine, Yonsei University Wonju College of 
Medicine, 20, Ilsan- ro, Wonju 26426, Korea.
E-mail: yubs@yonsei.ac.kr
*Ju-Hee Lee and Min-Seok Kim contributed 
equally to this work.
Copyright © 2019. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Ju-Hee Lee 
https://orcid.org/0000-0002-0858-0973
Min-Seok Kim 
https://orcid.org/0000-0002-8512-797X
Byung Su Yoo 
https://orcid.org/0000-0002-3395-4279
Sung-Ji Park 
https://orcid.org/0000-0002-7075-847X
Jin Joo Park 
https://orcid.org/0000-0001-9611-1490
Ju-Hee Lee , MD1,*, Min-Seok Kim , MD2,*, Byung Su Yoo , MD3, 
Sung-Ji Park , MD4, Jin Joo Park , MD5, Mi-Seung Shin , MD6, 
Jong-Chan Youn , MD7, Sang Eun Lee , MD2, Se Yong Jang , MD8, 
Seonghoon Choi , MD9, Hyun-Jai Cho , MD10, Seok-Min Kang , MD11, 
and Dong-Ju Choi , MD5
1 Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, 
Chungbuk National University College of Medicine, Cheongju, Korea
2 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 
Korea
3 Division of Cardiology, Department of Medicine, Yonsei University Wonju College of Medicine, Wonju, 
Korea
4 Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, Korea
5 Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital, 
Seongnam, Korea
6 Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, 
Korea
7 Division of Cardiology, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of 
Medicine, Hwaseong, Korea
8 Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, 
Korea
9 Division of Cardiology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of 
Medicine, Seoul, Korea
10Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
11Division of Cardiology, Department of Medicine, Yonsei University College of Medicine, Seoul, Korea
KSHF Guidelines for the Management 
of Acute Heart Failure: Part II. 
Treatment of Acute Heart Failure
INTRODUCTION
The number of patients with heart failure (HF) has been on the rise as a consequence of the 
aging of society and the improvement in screening and diagnostic techniques. Therefore, 
there is an increasing need for developing guidelines for the diagnosis and treatment of 
HF. Although guidelines for HF management have already been issued by American and 
European associations, many aspects of such guidelines do not reflect the domestic reality 
in Korea due to the social and anthropological characteristics of the Korean population. 
Thus, to help clinicians establish the best treatment plan for Korean patients with HF, it is 
necessary to develop specific guidelines that reflect the clinical situation in Korea. In 2012, 
the Korean Society of Heart Failure (KSHF) established the Guideline Writing Committee 
to develop the treatment guidelines for HF. The Korean guidelines for the diagnosis and 
management of chronic heart failure (CHF) were introduced in March 2016.1) However, CHF 
and acute heart failure (AHF) are distinct disease entities, warranting different approaches 
for diagnosis and treatment. Here, we introduce the Korean guidelines for the management 
of AHF with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). In Part 
II of this guideline, we discuss the treatment of AHF, including pharmacological and non-
pharmacological therapies, monitoring, and discharge.
This guideline was developed based on previously issued international guidelines and 
amended to reflect the clinical situation in Korea. A committee of KSHF members decided 
on the format of the guideline, the selection of topics addressed, and the composition of 
the Writing Committee. To develop the guidelines, we considered all clinical studies and 
evidence included in the international guidelines, as well as domestic research conducted 
in Korean patients with HF. Members of the Writing Committee first drafted thematic 
manuscripts, which were then assembled and arranged according to the evidence-
based scales. To ensure transparency and facilitate future revision of the guidelines, we 
documented the process followed for issuing a recommendation for each topic based on 
the gathered evidence. The guideline was drafted, reviewed by the advisory committee, 
and finalized after receiving endorsement from the Korean Society of Cardiology, Korean 
Society of Hypertension, Korean Society of Interventional Cardiology, Korean Society of 
Echocardiography, and Korean Society of Lipid and Atherosclerosis. While working on this 
guideline, the members of the Writing Committee were not affected by external influences 
and made every effort to exclude conflicts of interests.
The Writing Committee issued the level of recommendation upon a comprehensive 
analysis of evidence from studies describing real clinical experience, from surveys, from 
epidemiologic, observational, and randomized clinical studies, and from meta-analyses. 
The level of evidence and class of recommendation were defined so as to have a clear 
formulation, provide straightforward instructions, and be easily adopted in daily clinical 
practice (Supplementary Tables 1 and 2).
This guideline is intended to help improve clinical practice by providing recommendations 
based on clinical evidence. As such, the guideline does not serve as a basis for clinical 
judgement. The final decision in the treatment of each patient should be made by the treating 
physician according to their personal opinion and judgment, while using the guideline to 
support these decisions.
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PHARMACOLOGICAL TREATMENT
General considerations
AHF represents an acute exacerbation of existing HF (acute decompensated HF) or de novo 
HF with acute manifestation. In patients hospitalized for acute exacerbations, the prescribed 
medications for HF should be checked closely and adjusted if necessary. Angiotensin-
converting enzyme (ACE) inhibitors or angiotensin receptor blockers and beta-blockers can be 
maintained in most patients with HFrEF, based on the findings of clinical studies that reported 
better clinical outcomes in patients who continue HF medication than those who do not.2-5)
The reduction or discontinuation of beta-blockers may be considered only if: 1) beta-blocker 
use has been initiated or increased recently; 2) there is an excessive increase in blood volume; 
or 3) the cardiac output has remained marginal or has decreased. In patients with significant 
deterioration of renal function, temporarily reducing or discontinuing ACE inhibitor, 
angiotensin receptor blocker, and mineralocorticoid receptor antagonist may be considered 
until the renal function improves. It is important to reevaluate and control the medication 
at the time of admission in patients admitted due to HF deterioration. Beta-blockers should 
be started in the stable euvolemic patients after the successful discontinuation of initial 
intravenous diuretics, vasodilators, and inotropic agents. Beta-blockers should be started at 
low doses and only for stabilized patients.2-4) In addition, if a patient is not currently taking an 
ACE inhibitor, angiotensin receptor blocker, or mineralocorticoid receptor antagonist, these 
medications should be started as soon as possible after stabilization, with monitoring of 
renal function and blood pressure (see the Korean guideline for the management of CHF).1)
On the other hand, no studies support the survival benefit of medical treatments in patients 
with HFpEF. Moreover, there is no evidence to support the maintenance of some medications 
that achieved symptomatic improvement in HFpEF patients during acute exacerbations.
HF is a risk factor for venous thrombosis due to decreased cardiac output, increased 
peripheral venous pressure, and increased blood coagulability. Although several studies 
have confirmed that various anticoagulants can prevent venous thrombosis, there are 
multiple limitations to such studies. First, various anticoagulants and definitions of 
treatment response were used in different studies. Second, such studies covered a variety 
of acute illnesses but included only small populations of patients with AHF exacerbation. 
Third, the rates of clinically significant pulmonary embolism and mortality associated 
with anticoagulant use remain unclear. Nevertheless, to prevent venous thrombosis in 
hospitalized patients with decompensated AHF, anticoagulant use should be considered if 
the associated clinical benefit is high compared to the risk.6-8)
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1.  In HFrEF patients with acute exacerbation, the guideline-based medications should be continued 
if no hemodynamic instability or contraindications are evident (class of recommendation I, level 
of evidence B).
2.  Low-dose beta-blockers should be started in stable patients who achieve an euvolemic state, 
after discontinuing the initial intravenous diuretics, vasodilators, and inotropic agents (class of 
recommendation I, level of evidence B).
3.  If the clinical benefit of anticoagulant use is higher than the risk, anticoagulants should be used 
to prevent venous thrombosis (class of recommendation I, level of evidence B).
Diuretics
Unlike for ACE inhibitors and beta-blockers, the efficacy of diuretics in reducing HF-
associated mortality and morbidity has not been well studied. However, diuretics are 
recommended in patients with symptoms and signs of pulmonary congestion, to alleviate 
dyspnea and edema regardless of left ventricular ejection fraction, as administration of 
diuretics immediately upon admission to the emergency room is known to be associated 
with better outcomes.9)10) The goal of diuretic use is to maintain the patient's dry weight by 
using a minimum dose of diuretics to adjust the fluid volume. Once dry weight is reached, 
cardiac output is reduced due to hypotension and renal dysfunction from dehydration, and 
the diuretic dosage must be adjusted to facilitate the use of drugs such as ACE inhibitors. 
However, if the patient is not responding well to diuretics, right heart catheterization can be 
performed to confirm diastolic pressure and cardiac output. Once fluid excess is detected, 
the dose of loop diuretics should be increased to ensure that the appropriate concentration 
reaches the kidney.11)12) Compared to thiazide diuretics, loop diuretics cause intensive 
diuresis for a shorter period of time. It is recommended that intravenous furosemide 20–40 
mg be initially administered in patients with AHF who did not use oral diuretics, as well as 
in those with acute exacerbation of CHF. Thiazide is less effective in patients with reduced 
renal function. Although loop diuretics are preferred to thiazides in patients with HFrEF, 
synergistic effects can be seen with combination therapy (loop diuretics with thiazides) in 
patients with resistant edema. Therefore, diuretics based on different mechanisms may be 
added in patients with inadequate symptom relief.13-15)
In the initial treatment of AHF, it is necessary to measure daily body weight, blood pressure 
in the supine and erect positions, and fluid intake and output. In addition, since loop 
diuretics may reduce glomerular filtration rate, worsen neurohumoral activity, and cause 
electrolyte imbalance, it is recommended to measure electrolyte levels and renal function 
daily during diuretic treatment or during a period when the HF medication dose is adjusted. 
Patients are often instructed to adjust their diuretic dose by themselves, so symptoms/signs 
of congestion and body weight should be measured daily. Although diuretics can relieve 
congestive symptoms, their effects on mortality are not well studied.
A randomized controlled study of 20 patients reported that, compared to single-dose 
administration, continuous infusion of diuretics was more effective and less toxic.16) 
However, the DOSE randomized study, which enrolled 308 patients, reported no significant 
difference between these administration modalities regarding symptom relief or renal 
toxicity.12) On the other hand, intravenous administration of low-dose dopamine with loop 
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1.  In AHF patients with fluid retention, a parenteral diuretic should be used with careful monitoring 
of symptoms, urine output, electrolyte balance, and renal function (class of recommendation I, 
level of evidence B).
2.  In patients without oral diuretic therapy, the initial recommended dose of loop diuretics is 
furosemide 20–40 mg, and at least the same dosage of loop diuretics should be used in patients 
with acute exacerbation of CHF (class of recommendation I, level of evidence B).
3.  The intermittent or continuous injection of diuretics is recommended, and the dose and 
duration should be adjusted according to the patient’s symptoms and clinical condition (class of 
recommendation I; level of evidence B).
4.  If symptoms do not improve even with loop diuretic use, it is advisable to add other diuretics 
such as thiazide or spironolactone (class of recommendation IIa, level of evidence B).
diuretics reportedly increases diuresis and preserves renal function.17) Further clinical studies 
are needed to clarify the optimal administration modality for diuretic treatment.
Intravenous vasodilators
Intravenous vasodilators include nitrates, nitroprusside, and nesiritide (Table 1). Intravenous 
nitrates rapidly reduce pulmonary congestion by lowering preload through a vasodilatory 
effect.18)19) Thus, the use of intravenous nitrates is helpful for relieving dyspnea in HF patients 
with hypertension, myocardial ischemia, or clinically significant mitral regurgitation. 
However, caution should be taken because drug resistance occurs in about 20% of patients, 
who no longer respond to high drug concentrations.20-22)
Nitroprusside is a commonly used balanced vasodilator with dual benefit that consists of 
decreasing venous tone (optimize preload) and arterial tone (decrease afterload). However, 
few studies have described the efficacy of this drug. Therefore, when administering 
nitroprusside, hemodynamic changes should be monitored frequently using invasive blood 
pressure monitoring methods. The long-term use of nitroprusside may result in isocyanate 
toxicity, which manifests as loss of appetite, general weakness, and altered mentality; 
therefore, caution should be taken in patients with impaired renal function. Because 
nitroprusside can cause serious hypotension, it is mainly used in intensive care settings 
and can be expected to be effective in patients with a combination of severe pulmonary 
congestion and hypertension or severe mitral regurgitation and cardiac dysfunction.23)
Nesiritide has been shown to reduce left ventricular filling pressure, per the findings of a 
large randomized study of patients with decompensated AHF. While no favorable effects 
on mortality, re-admission rate, or renal protection were noted, there was a statistically 
significant benefit regarding dyspnea relief, though the risk of hypotension was increased.24)25)
Overall, no clinical studies reported that intravenous vasodilators improve clinical 
outcomes in hospitalized patients with HF. Among hospitalized patients with AHF, the 
use of intravenous vasodilators is limitedly recommended to relieve dyspnea in patients 
without hypotension. In particular, intravenous vasodilators can induce excessive lowering 
of blood pressure, which may be associated with increased mortality in AHF patients.24)25) 
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1.  Intravenous vasodilators may improve AHF symptoms in patients with systolic blood pressure 
>90 mmHg, and it is advisable that symptoms and blood pressure be monitored frequently during 
intravenous injection (class of recommendation IIa, level of evidence B).
2.  In patients with hypertensive AHF, intravenous vasodilators can be used to improve patient 
symptoms and reduce congestion (class of recommendation IIa, level of evidence B).
Table 1. Intravenous vasodilators for the treatment of AHF
Vasodilator Recommended dose Main side-effects Other observations
Nitroglycerine Start with 10–20 µg/min; 
increase to 200 µg/min
Hypotension, headache Tolerance with continuous use
Nitroprusside Start with 0.3 µg/kg/min; 
increase to 5 µg/kg/min
Hypotension, 
isocyanate toxicity
Light sensitivity
Isosorbide dinitrate Start with 1 mg/hr, 
increase up to 10 mg/hr
Hypotension, headache Tolerance with continuous use
Nesiritide Bolus 2 µg/kg 
+ infusion 0.01 µg/kg/min
Hypotension -
AHF = acute heart failure.
Thus, all changes in symptoms and blood pressure should be closely monitored. Moreover, 
intravenous vasodilator injections should be given more cautiously in patients with HFpEF, 
who are more sensitive to volume changes. Special attention should be paid to the use of 
intravenous vasodilators in patients with mitral stenosis or aortic stenosis.
Intravenous inotropic agents and vasopressors
Intravenous inotropic agents are drugs that increase cardiac output and have been used in 
AHF (Table 2). However, there is a lack of evidence regarding the clinical efficacy of drugs 
such as dobutamine and milrinone. In some small-scale clinical studies, dobutamine 
improved hemodynamic indices in patients with AHF; however, large-scale studies could not 
confirm such efficacy.26)27) Because there is insufficient evidence for clinical effectiveness and 
side-effects such as arrhythmia or myocardial ischemia, intravenous inotropes should only be 
used when tissue perfusion is severely impaired, with low cardiac output.28)
Inotropes such as dobutamine are medications that increase myocardial contractility and are 
widely used in patients with low blood pressure due to a severely decreased blood supply to 
the major organs. However, there is concern that these drugs can increase the risk of death 
associated with exacerbate myocardial ischemia and arrhythmia induced by the increased 
heart rate. Milrinone, a phosphodiesterase antagonist that does not act on beta-receptors, 
can theoretically be used even in patients who take beta-blockers and moreover has the 
advantage of lowering pulmonary vascular resistance. However, milrinone should be used 
cautiously because it can lower systemic blood pressure.29-32)
Vasoconstrictors such as norepinephrine, which acts on the peripheral arteries, are 
commonly used in patients with severe hypotension. These medicines increase blood 
pressure and reduce the blood supply above the lower limbs, thereby maintaining blood flow 
to the major organs. Norepinephrine and epinephrine are the most commonly used and have 
the effect of increasing myocardial contractility similar to intravenous inotropes. However, 
these medications can increase the afterload of the left ventricle and thus should be used only 
in patients with insufficient blood supply to the major organs despite adequate ventricular 
filling pressure.
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1.  To increase cardiac output, elevate blood pressure, and improve peripheral perfusion, short-term 
intravenous infusion of inotropic agents may be considered in patients with hypotension, signs/
symptoms of hypoperfusion, or shock despite adequate filling status (class of recommendation 
IIa, level of evidence C).
2.  If the cause of hypoperfusion is related to the use of beta-blockers, the use of the 
phosphodiesterase antagonist, milrinone may be considered under continuous 
electrocardiographic and arterial blood pressure monitoring (class of recommendation IIb, level of 
evidence C).
3.  In patients with persistent cardiogenic shock despite the use of intravenous inotropic agents, the 
use of vasoconstrictors such as dopamine or norepinephrine to increase blood pressure and blood 
flow to major organs may be considered under continuous electrocardiography and arterial blood 
pressure monitoring (class of recommendation IIb, level of evidence C).
4.  In HF patients with pulmonary congestion, intravenous inotropic agents should not be used 
unless there is hypotension, signs of hypoperfusion to major organs, or shock, because it may 
cause serious arrhythmias or myocardial ischemia leading to death (class of recommendation III, 
level of evidence C).
Dopamine increases myocardial contractility at relatively high doses (>5 μg/kg/min), 
contracts the blood vessels, and increases systemic blood pressure. However, at lower doses 
(3 μg/kg/min), dopamine can selectively dilate the renal blood vessels and increase urine 
volume. However, since dopamine may cause hypoxemia, oxygen saturation should be 
monitored, and supplementary oxygen administration may be required.33)
Antiarrhythmic agents
Because of the increased morbidity and mortality associated with atrial and ventricular 
tachyarrhythmia in HF patients, several studies have investigated the use of antiarrhythmic 
agents. However, most antiarrhythmic agents did not increase the survival rate; these 
studies rather found that antiarrhythmic agents increased the mortality rate.34-36) Most 
class I and class III antiarrhythmic agents have a beta-receptor blocking effect and thus are 
very likely to have an increased risk of HF deterioration when used in patients with AHF. 
Digoxin and amiodarone are the only medications that can be considered for treating atrial 
tachyarrhythmia in patients with AHF.
Digoxin is the first drug to consider when attempting to control heart rate in HF patients 
with atrial fibrillation. When heart rate is >110 bpm, intravenous digoxin 0.25–0.5 mg may 
be considered in digoxin-naïve patients. However, attention should be paid because digoxin 
increases the risk of arrhythmia in patients with renal dysfunction or electrolyte abnormalities. 
Because several clinical studies confirmed that amiodarone does not increase mortality, its use 
for controlling atrial tachyarrhythmia may be considered in patients with AHF.37-39)
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1.  Digoxin use is advised in patients with AHF and atrial fibrillation (class of recommendation IIa, 
level of evidence C).
2.  The use of amiodarone can be considered in the presence of atrial fibrillation concomitant with 
AHF (class of recommendation IIb, level of evidence B).
3.  Other antiarrhythmic agents except for amiodarone should not be used to treat atrial and 
ventricular tachyarrhythmia (class of recommendation III, level of evidence A).
Table 2. Positive inotropes and vasopressors used to treat AHF
Drug Bolus Infusion rate Effects
Dobutamine Not recommended 2–20 µg/kg/min Increase cardiac contractility via 
interaction with beta-receptors
Dopamine Not recommended <3 µg/kg/min Dilate renal blood vessels
3–5 µg/kg/min Increase cardiac contractility via 
interaction with beta-receptors
>5 µg/kg/min Increase cardiac contractility via 
interaction with beta-receptors
Vasoconstriction via interaction with 
alpha-receptors
Milrinone 25–75 µg/kg over 10–20 min 0.375–0.75 µg/kg/min Increase cardiac output and heart rate
Decrease systemic and pulmonary 
vascular resistance
Levosimendan 12 µg/kg over 10 min 0.1 µg/kg/min 
(0.05–0.2 µg/kg/min)
Increase cardiac contractility via 
increased Ca2+ sensitivity
Vasodilation via interaction with the 
ATP-dependent Ca2+ channel
Norepinephrine Not recommended 0.2–1.0 µg/kg/min Vasoconstriction
Epinephrine During resuscitation: 1 mg 
intravenously and every 3–5 min
0.05–0.5 µg/kg/min Vasoconstriction
New drugs
Vasopressin receptor antagonists allow the elimination of free water via urination without 
electrolyte loss. Among such drugs, tolvaptan is a selective oral vasopressin V2 receptor 
antagonist that inhibits free water reabsorption in the renal tubule and helps treat HF-related 
volume overload refractory to diuretic therapy.40) In HF patients with volume overload and 
hyponatremia, tolvaptan effectively improved hyponatremia.40) For treating hyponatremia, 
vasopressin receptor antagonists may be considered in AHF patients in whom hyponatremia 
persists despite adequate treatment including water restriction. However, further clinical 
studies are needed to clarify the long-term clinical efficacy and safety of such drugs.
Serelaxin reduces systemic vascular resistance and increases blood flow to the renal vessels, 
increasing cardiac output. Serelaxin is also known to participate in various cellular processes 
with antioxidative, anti-inflammatory, and antifibrotic actions.41) A recent large-scale clinical 
trial found that the intravenous injection of serelaxin for 48 hours at the initial stage of 
AHF caused rapid hemodynamic improvement, which ameliorated symptoms associated 
with pulmonary congestion and improved some clinical outcomes including 180-day 
mortality.42-45) However, the clinical use of serelaxin is not yet approved in the United States or 
Europe, warranting the need for data on long-term patient prognosis and stability.
DEVICE THERAPY AND SURGICAL TREATMENT
Ultrafiltration
Diuretics are important in the treatment of congestion and fluid retention in AHF. However, 
if congestion is severe, ultrafiltration can be considered. Several early clinical trials have 
confirmed that ultrafiltration can effectively remove excessive fluid in the initial treatment 
of HF46)47) and moreover provides the advantage of increased weight loss and reduced 
rehospitalization rate.48)49) However, in a subsequent clinical study including patients with 
cardio-renal syndrome undergoing ultrafiltration versus medical treatment, ultrafiltration 
had negative effects in terms of renal dysfunction, persistent congestion symptoms, and renal 
function at 96 hours.50)51) A recent meta-analysis on the usefulness of ultrafiltration reported a 
beneficial effect on weight loss but no effect on creatinine reduction or mortality.52)
Because ultrafiltration is invasive, its use should be considered according to the physician's 
experience, advice of nephrologist, and the additional cost. To remove excessive fluid, 
ultrafiltration may be considered in some AHF patients whose conditions are refractory to 
medical treatment including diuretic therapy.
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1.  Ultrafiltration may be used to remove excessive fluid and improve congestion symptoms in AHF 
patients with fluid retention (class of recommendation IIb, level of evidence B).
2.  Ultrafiltration may be considered in patients with congestive HF unresponsive to conventional 
medical therapy (class of recommendation IIb, level of evidence C).
1.  In patients with AHF, vasopressin receptor antagonists may be considered when severe 
hyponatremia persists despite appropriate treatment including water restriction (class of 
recommendation IIb, level of evidence B).
Intra-aortic balloon pump
The use of an IABP increases cardiac output by the balloon situated inside the aorta deflates 
quickly at the start of ventricular systole results in decreasing cardiac afterload, and then 
expands during ventricular diastole to allow blood to move farther into the proximal aorta. 
IABP is used in AHF patients with cardiogenic shock, low cardiac output, and reduced 
ventricular contraction if hypoperfusion persists in multiple organs; however, the benefit 
of IABP use has only been clinically proven in a small number of cases. It is difficult to 
conduct clinical studies on patients with acute heart attack accompanied by cardiogenic 
shock. For this reason, evidence regarding the clinical outcomes of such patients is largely 
based on retrospective research or single-center case reports or studies, which could not 
exclude patient selection bias. A meta-analysis found that IABP use did not affect in-hospital 
mortality in patients with AMI but no cardiogenic shock; however, among patients with 
accompanying cardiogenic shock, IABP use was associated with a large and significant (28%) 
decrease in mortality rate.53) Another meta-analysis, which included patients with AMI and 
cardiogenic shock, IABP use did not affect in-hospital mortality among patients who received 
medical therapy without coronary revascularization, was associated with a significant 
decrease in mortality among patients treated with thrombolytics, and was associated with 
a significant increase in mortality among patients who underwent percutaneous coronary 
intervention; however, in the overall population of patients included in the analysis, there 
was no significant inter-group difference regarding in-hospital mortality rates.54) A similar 
influence of treatment method on the effectiveness of IABP use was also reported regarding 
30-day mortality rates.55) In the IABP-SHOCK II study, which proved the efficacy of IABP 
in patients with AMI accompanied by cardiogenic shock, most patients first underwent 
percutaneous coronary intervention; the 30-day and 12-month mortality rates did not 
differ between the control group and the IABP group.56)57) Therefore, if percutaneous 
coronary intervention is performed as primary treatment for AMI, routine IABP use is 
not recommended in patients with AMI, even in the presence of concomitant cardiogenic 
shock.53)55-57) To date, no randomized large-scale studies have reported data on the outcomes 
of patients with AMI and accompanying cardiogenic shock due to mechanical complications 
such as ventricular septal defect or papillary muscle rupture. However, based on reports 
from some single institutes and on retrospective observational study results, IABP use may 
be helpful as a bridge for hemodynamic stabilization before surgical correction.58)59) No 
significant clinical research has evaluated the effectiveness of IABP use in patients with left 
ventricular systolic dysfunction due to causes other than acute coronary syndrome.60-62)
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1.  It is reasonable to use an intra-aortic balloon pump (IABP) in patients with AHF in a state of 
cardiogenic shock due to mechanical causes (e.g., ventricular septal rupture, acute mitral 
insufficiency) accompanied by acute myocardial infarction (AMI) (class of recommendation IIa, 
level of evidence C).
2.  The routine use of IABP in patients with AHF and cardiogenic shock accompanied by AMI is not 
recommended (class of recommendation III, level of evidence B).
Mechanical circulatory support and cardiac transplantation
The use of a mechanical circulatory support device (MCSD) may be effective in 
hemodynamically unstable patients with decompensated AHF despite sufficient cardiac 
stimulation. MCSD use should be considered in cases in which a decision cannot be made 
about additional treatments such as heart transplantation or use of a surgical or implantable 
LVAD, as well as in cases in which recovery of heart function could be expected. However, 
MCSD use may be helpful only for the duration of several hours or days. If the patient is not a 
good candidate for LVAD implantation, the MCSD may have to be removed. Since MCSD use 
requires anticoagulant therapy, it carries the risk of complications such as thrombosis and 
hemorrhage; additionally, distal ischemia may occur during the process of catheter insertion 
and maintenance treatment. Therefore, careful consideration is necessary when deciding 
whether or not to use an MCSD.
The use of ECLS, typically in the form of extracorporeal membrane oxygenation, became 
more widespread starting in 2000, when Bartlett et al. reported a 44% increase in 
survival rate among patients with cardiogenic shock.63) The use of ECLS in AHF increased 
exponentially since Chen et al.64) reported a significant increase in survival rate associated 
with ECLS use during cardiopulmonary resuscitation for acute cardiac arrest due to a cardiac 
disorder. Eighty-four studies including a total of 1,494 patients analyzed the efficacy of ECLS 
in AHF or cardiac arrest and confirmed its usefulness.65)
Recently developed percutaneous ventricular assist devices such as TandemHeart and Impella 
are widely used overseas. Small randomized studies found that the temporary use of an LVAD 
was associated with short-term hemodynamic improvement, but the effect on survival rate 
was unclear.66-68) The extensive use of a temporary LVAD is difficult to implement in Korea due 
to economic constraints but may be considered depending on patient's state. Such MCSDs 
have their own merits, demerits and characteristics, which warrants restriction of their use, 
along with adequate indications.69) ECLS is superior to other strategies if both ventricles must 
be assisted simultaneously or if oxygenation capabilities are compromised.70) TandemHeart, 
a percutaneous ventricular assist device approved for domestic use in Korea, can be used as 
an implantable LVAD if the intravenous catheter is left in the left atrium. However, the use 
of TandemHeart is limited because it requires atrial septal puncture and as well as much 
expensive than ECLS. Therefore, in Korea, it is reasonable to prioritize the use of ECLS in 
AHF refractory to existing drug treatments.71)
Cardiac transplantation is the most fundamental treatment in patients with terminal HF 
refractory to drug treatment. Transplantation is commonly chosen in patients with CHF, but also 
in some patients with AHF, cardiogenic shock, and cardiac arrest who received a percutaneous 
circulatory support device that could not be successfully removed. However, in such cases, cardiac 
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1.  It is reasonable to use extracorporeal life support (ECLS) in patients with AHF and acute cardiac 
arrest refractory to existing drug therapies (class of recommendation IIa, level of evidence B).
2.  It is reasonable to use ECLS when HF is unresponsive to drug treatment and progresses to 
cardiogenic shock (class of recommendation IIa, level of evidence B).
3.  It is reasonable to use a percutaneous ventricular assist device before deciding the indication for 
cardiac transplantation or implantation of a left ventricular assist device (LVAD) in patients who 
are hemodynamically unstable and suspected to have organ damage (class of recommendation 
IIb, level of evidence B).
transplant surgeries mostly proceed before sufficient pre-transplantation evaluation of the 
patient's state can be performed, and the long-term prognosis after transplantation is poor. 
Therefore, the choice of cardiac transplant surgery should be made carefully.
Surgical correction
Acute cardiac failure can be caused by mechanical complications secondary to various 
cardiovascular diseases. Patient prognosis can be improved by appropriate surgical therapy 
(Table 3).72)73) Echocardiography is very important for differential diagnosis and in deciding 
the treatment methods.
Ventricular free wall rupture occurs in 0.8–6.2% of patients with myocardial infarction 
(MI).74) Making an early diagnosis is difficult because, if pericardial tamponade occurs, most 
patients die within a few minutes. However, it is possible to make the diagnosis in subacute 
cases involving thrombosis or adhesion at the rupture site. Rupture causes cardiogenic 
shock, rapid falls in blood pressure, and mental deterioration or loss of consciousness; in 
some patients, such symptoms are preceded by chest pain, nausea, ST-segment elevation, 
and T-wave changes.75) If ventricular free wall rupture is suspected, echocardiography 
must be conducted immediately. The diagnosis of ventricular free wall rupture can be 
established if there are signs of paroxysmal events and pericardial effusion >1 cm is noted.76) 
Pericardiocentesis, fluid infusion, and intravenous inotropics can be considered for 
stabilizing the patient's hemodynamics, but surgery must not be delayed.
Ventricular septal rupture was originally thought to occur within 1–5 days of MI in 1–2% of 
patients, but these rates have been decreasing due to the improvements in MI diagnosis 
rates.77-79) AHF and cariogenic shock are usually followed by MI, and ventricular septal rupture 
is suspected in patients with signs of pansystolic murmur in the left lower sternal border. 
Echocardiography can be used to confirm the diagnosis and assess the perforation location 
and size, as well as to determine whether mitral value pathology is present. In order to avoid 
expansion of the rupture, surgery must be considered as soon as ventricular septal rupture is 
diagnosed, regardless of whether hemodynamic stability is maintained.
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Table 3. Indication for surgical treatment in patients with AHF
Indication for surgical treatment
Cardiogenic shock in MI patients with multi-vessel coronary artery disease
Ventricular septal rupture
Ventricular free wall rupture
Acute exacerbation of valvular heart disease
Failure or thrombosis of a prosthetic valve
Rupture of an aortic aneurysm into the pericardium, or aortic dissection
Ischemic papillary muscle rupture or malfunction, chorda rupture, endocarditis, or acute mitral insufficiency due 
to external injury
Endocarditis, aortic dissection, or acute aortic insufficiency caused by closed chest trauma
Ruptured aneurysm of the sinus of Valsalva
Acute exacerbation of cardiac insufficiency in patients receiving mechanical circulatory support
Hemodynamically unstable pulmonary embolism for which thrombolytic treatment is not possible
Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of 
Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, 
European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of 
Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology.  
AHF = acute heart failure; MI = myocardial infarction.
Acute mitral insufficiency within 2–7 days occurs in 10% of patients who experience 
cariogenic shock after MI80) but can also be caused by total or partial papillary muscle 
rupture, papillary muscle dysfunction, trauma, and endocarditis, and can be accompanied 
by severe pulmonary congestion and cariogenic shock. Since an apical systolic murmur 
might not be clearly heard due to a sharp rise in left atrial pressure, it is crucial to conduct 
an echocardiographic evaluation to check for mitral insufficiency and assess left ventricular 
systolic function. Transesophageal echocardiography might also be needed in some cases. If 
acute mitral insufficiency is diagnosed, surgery must be considered immediately.81)
Paroxysmal events of AHF can also be caused by prosthetic valve thrombosis, aortic disease, 
acute aortic insufficiency, or severe pulmonary embolism. Echocardiographic evaluation is 
needed to differentiate these diseases and plan appropriate treatment.
MONITORING ACUTE HEART FAILURE PATIENTS
Symptoms of AHF include dyspnea on exercise, orthopnea, paroxysmal nocturnal dyspnea, 
peripheral edema, abdominal discomfort, nausea, and vomiting. As most AHF patients show 
symptoms of dyspnea, the improvement in dyspnea represents a crucial aspect of treatment 
response and thus should be monitored. Orthopnea, one of the symptoms of AHF patients, 
has the strongest correlation with elevated pulmonary capillary wedge pressure, providing 90% 
sensitivity.82) However, there are many cases in which symptoms disappear after diuretic therapy 
even though left ventricular filling pressure remains elevated. Thus, improvement in symptoms 
such as dyspnea cannot be the sole criterion for judging treatment effectiveness.83)84)
Physical examinations used to assess congestion include evaluation of body weight, jugular 
venous pressure, and rales on auscultation, as well as the assessment of edema. Change in 
body weight can be caused by malnutrition or cardiac cachexia, but daily weight fluctuations 
are usually related to fluctuations in residual body fluid. Therefore, to assess congestion, 
it is important to obtain an accurate estimate of body weight. This can be achieved using 
a standardized scale with a precision of 50 g units and conducting measurements at pre-
established times before urinating, eating, or taking drugs. It is commonly known that 
jugular venous pressure reflects right atrial pressure, which in turn reflects left ventricular 
filling pressure, which essentially corresponds to the pulmonary capillary wedge pressure.83) 
Jugular venous pressure represents an accessible indicator of congestion and is helpful 
for monitoring the effectiveness of HF treatment, having been shown to predict the 
rehospitalization rate.85) However, caution should be exercised when interpreting jugular 
venous pressure values in patients with primary pulmonary hypertension or tricuspid 
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1.  In AHF patients, heart rate, rhythm, blood pressure, respiration rate, and oxygen saturation must 
be continuously monitored (class of recommendation I, level of evidence C).
2.  The effectiveness of hypervolemia correction must be checked on a daily basis through the 
assessment of symptoms (class of recommendation I, level of evidence C).
3.  When starting diuretics injections or renin-angiotensin-aldosterone antagonist treatment, renal 
function and serum electrolyte levels (sodium, potassium, etc.) must be checked daily (class of 
recommendation I, level of evidence C).
4 .  Using an arterial line to monitor blood pressure can be helpful in patients with low blood 
pressure or those with persistent symptoms despite treatment (class of recommendation IIa, 
level of evidence C).
insufficiency. Furthermore, it is challenging to measure and interpret jugular venous pressure 
in obese patients and in those with respiratory diseases.
The presence of rales on auscultation can indicate fluid overload, which can be caused by 
but is not specific to HF. Moreover, the absence of rales on auscultation does not mean that 
the lung is clear of pulmonary congestion, so interpretations must be done with caution.83) 
Similarly, chest radiography cannot accurately identify the presence of congestion in HF 
patients.83) Peripheral edema in HF patients is usually connected to elevated right atrial 
pressure due to left ventricular failure. Lower-extremity edema may resolve with diuretic 
therapy, but the excess fluid may be redistributed toward the sacrum because such patients 
spend most of their time in bed. The redistribution of excess fluid into the sacral area can be 
suspected if lower-extremity edema improves without weight loss.
Right cardiac catheterization represents the most standardized method of monitoring 
congestion and perfusion in HF patients. However, routine use of invasive monitoring is not 
advised; rather, it should only be performed if it is difficult to determine treatment direction by 
non-invasive methods (for details, please refer to section Right heart catheterization of Part I of this 
guideline, which discusses invasive diagnostic methods including right cardiac catheterization).
HOSPITAL DISCHARGE
Treatment objective
Since HF patients have high readmission and mortality rates after discharge, attainable 
treatment objectives must be established and suitable education should be provided before 
discharge.86-92) The following aspects must be assessed before hospital discharge: state of 
acute aggravating factors; whether symptoms and signs of HF including congestion have 
improved; whether the maintenance dose of oral diuretics is stable. The following must 
be comprehensively assessed and confirmed: whether critical medication to improve HF 
prognosis is being injected at the right dosage; whether the patient is aware of medication 
usage precautions; how well appropriate treatments were implemented during hospitalization; 
whether appropriate assessment and treatment of associated diseases is maintained; whether 
the patient is well educated about smoking, eating, and exercise requirements; and whether 
the patient or their guardian has the capacity to manage the situation.92-95)
Improving quality of medical treatment using clinical quality indicators
Clinical quality can be understood as the degree of achieving the desired outcome and 
scientific relevance. Terms that refer to indicators measuring clinical quality are quality 
indicator, clinical indicator, and performance measure.96) Generally, the definition of a 
quality indicator includes the quantitative tool itself and is considered the same as a clinical 
quality indicator. Worldwide, there is a need to amass more data and conduct further 
evaluations in order to develop powerful quality indicators.
Domestically, medical institutions conduct quality evaluations based on clinical quality 
indicators aiming to improve clinical quality in MI patients. Moreover, the quality of medical 
34https://e-kcj.org https://doi.org/10.4070/kcj.2018.0349
Korean Guidelines for Acute Heart Failure: Part II
1.  In HF patients, a clear and attainable treatment objective must be established, and appropriate 
education must be conducted prior to discharge (class of recommendation I; level of evidence A).
institutions or clinical systems can be compared using disease-specific quality indicators that 
include information obtained during diagnosis, treatment, post-discharge management, 
and outpatient follow-up. A recent trend is to use prognostic indicators to develop relevant 
performance measures. To do so for HF patients, further post-discharge outcome data should 
be collected from individual studies and, possibly, national health registries.96-98)
The American College of Cardiology recommends employing the following prognostic 
indicators: overall HF-related mortality, 30-day mortality, HF readmission rate, and 30-day 
readmission rate due to HF. Other performance measures include left ventricle ejection fraction 
during hospitalization, number of outpatient appointments, and use of ACE inhibitors/
angiotensin receptor blockers and beta-blockers in hospitalized patients with HFrEF.99)
Maeda conducted a systematic review with 2 prospective cohort studies and a randomized 
study, concluding that patients who received post-discharge ACE inhibitors/angiotensin 
receptor blockers and beta-blockers as well as pre-discharge education using printed materials 
had improved prognosis, but the benefit was not reflected in measuring left ventricular 
parameters or counselling for smoking cessation.100) Fonarow et al.101) recently reported a 
multi-center prospective interventional clinical trials to determine the impact of various 
clinical performance indicators in terms of mortality rates. Treatment with ACE inhibitors/
angiotensin receptor blockers, beta-blocker therapy, HF education, and use of an implantable 
cardioverter defibrillator reduced mortality rates by 49%, 55%, 31%, and 36%, respectively.101)
Domestic studies indicated that medication use during hospitalization affects the long-term 
prognosis of AHF patients and the use of ACE inhibitors/angiotensin receptor blockers and 
beta-blockers significantly decreases mortality rates. The representative clinical quality 
indicators can be selected based on these domestic and international evidence.102)103) 
However, the lack of a platform for standardized patient education, low self-care ability, and 
limitations of the self-reporting system preclude the uniform application of international 
performance parameters in the domestic context. To improve clinical quality and prognosis 
of Korean patients with HF, the development and use of performance or clinical quality 
indicators must be promoted.
Management programs for heart failure patients
Among HF patients, self-care represents a challenging and multidimensional issue.104) 
Patients must understand how to monitor their symptoms and weight loss, restrict their salt 
intake, take medication as prescribed, and remain physically active. In fact, many HF patients 
need to participate in disease control educational programs, even after discharge (Table 4). 
Patients who received education within the hospital have more knowledge regarding HF both 
at discharge and at 1 year after discharge.105) One study reported that pre-discharge education 
decreased the hospitalization duration within 6 months after the initial discharge, thereby 
also decreasing costs and death rates.89)
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1.  A multidisciplinary HF management program should encourage patients with a high risk of 
readmission to receive guideline-based treatments in order to decrease HF-related readmissions 
(class of recommendation I, level of evidence A).
2.  It is reasonable to schedule hospital visits within 1–2 weeks from discharge or phone follow-up 
within 3 days from discharge (class of recommendation IIa, level of evidence B).
Before hospital discharge, the acute phase of HF must be resolved. There must be no 
congestion, and oral diuretic prescriptions must have remained stable for at least 48 
hours before the patient can be considered for discharge.88)90)106) Treatment regimens with 
agents such as beta-blockers, which can improve the long-term progression of HF, must be 
optimized, and appropriate education should be provided to patients, family members, and 
other caretakers. Care before and after discharge must follow the standardized consultation 
guide provided by the Korean Heart Failure Association, as such an approach has been shown 
to improve prognosis. Caution should be taken when administering beta-blockers to patients 
who received an inotropic drug during hospitalization, as well as when administering 
ACE inhibitors/angiotensin receptor blockers or aldosterone antagonists to patients who 
experienced severe azotemia or to patients at high risk for hyperkalemia. Body fluid levels 
must be maintained and blood pressure must be properly controlled. In patients with atrial 
fibrillation, heart rate must also be well controlled. Hospitalization can be an opportunity 
for educating patients and family members, while health management teams can plan 
appropriate treatments.
HF patients, especially those who are hospitalized repetitively, have poor prognosis and are 
vulnerable, especially during the transition from inpatient to outpatient status because of the 
naturally progressive nature of HF, complicated medication prescriptions, concomitant diseases, 
and involvement of many doctors. Patient education and printed materials should be provided 
during hospitalization and upon discharge. The printed material must include guidelines for 
appropriate activity levels, meals, discharge prescriptions, outpatient appointments, weight 
control, and actions to be performed when symptoms worsen (Table 5).86) Post-discharge 
medication treatment plans based on guidelines improve treatment results.86)92)94)107) Many 
studies reported an association of improved treatment results with stronger discharge 
guidance on HF and unified follow-up.87)108)109) The addition of an hour of standardized 
HF guidance and education delivered by a nurse specialist at discharge enhanced clinical 
treatment results and self-care ability, leading to effective treatment maintenance, decreased 
medical costs, and reduced readmission and death rates.89)
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Table 4. Pre-discharge management and strategy for long-term management of AHF
Pre-discharge management and long-term management strategy
Plan follow-up strategy
Register for disease control programs, receive education, and plan appropriate lifestyle changes
Optimize medication dosage
Consider the usage of appropriate treatment aids
Prevent early readmission
Alleviate symptoms; improve quality of life and survival rates
AHF = acute heart failure.
Table 5. Matters that must be addressed by HF management programs
Essentials in HF management program
Optimizing drug treatment and appliance therapy
Education on relevant topics including treatment compliance and self-care
Education on self-monitoring symptoms and controlling diuretics
Optimizing the follow-up strategy, including the timing of visits to the clinic, calling in and remote monitoring
Handling acute exacerbation
Appropriate adjustments according to changes in weight, nutritive condition, activity level, quality of life, and 
blood tests findings
Additional treatment plans in case of HF progression
Psychosocial support for the patients and their families
HF = heart failure.
Many aspects other than patient education are important for the success of follow-
up management. All aspects of the patient's medical treatment, especially changes in 
prescription or additional diagnostic information, must be recorded clearly and in a timely 
manner to avoid misunderstandings between the many specialists that might handle follow-
up management. One other important factor that must be addressed during transitional 
management is letting the patient and guardian know what will happen in the clinic, 
giving information about medication control and plans for follow-up management, and 
preparing them for detecting possible signs or symptoms of deterioration. Early follow-up 
after discharge can minimize the delay between a change in the patient's condition and the 
corresponding adjustment in the treatment plan, which will increase the understanding of 
the patient's condition and lower the risk of readmission.110) Additional visits to the hospital 
within 7–14 days post-discharge or phone follow-up within 3 days is considered appropriate. 
Effective follow-up management of HF requires a good understanding of the socioeconomic 
and mental context of each patient, as well as providing the patient with adequate educational 
materials and inclusive plans, which are helpful for increasing self-care ability.111-113)
Management plans for HF patients must incorporate guideline-based treatment methods. 
The HF patient and clinician must aim to establish a suitable time schedule for follow-up 
management, to clarify the requirements for meals and physical activity levels, and to plan 
cardiac rehabilitation and continuous education regarding complications, standardized 
management guidelines for cardiovascular diseases, and secondary prevention of such 
disease. Clinicians must also be aware of the psychosocial, ethological, and socioeconomic 
issues that HF patients and their caregivers might face.114-119)
Palliative care
There are many cases in which HF progression becomes unpredictable, so it is difficult to 
decide when to start providing palliative care. However, palliative care is usually considered 
in patients who require repeated hospitalization for multiple acute episodes despite 
optimized drug treatment, who are not candidates for cardiac transplantation or MCSD 
use, and who experience symptoms of New York Heart Association functional class IV 
accompanied by a chronic decrease in quality of life, cardiac cachexia, low serum albumin 
levels, or imminent death. In such patients, the focus of treatment shifts to improving quality 
of life, controlling symptoms, promptly detecting and treating acute exacerbations, and 
generally maintaining the patient's well-being from a physical, mental, social, and spiritual 
perspective. Moreover, in HF patients, palliative care should aim to completely resolve the 
symptoms of associated diseases by addressing the patient's physical, mental, and religious 
demands. Furthermore, the palliative treatment strategy should clarify the conditions under 
which cardiopulmonary resuscitation need not be conducted or the implantable cardioverter 
defibrillator should be stopped.
CONCLUSION
In this part of guideline, the treatment of AHF, including pharmacological and non-
pharmacological therapies, monitoring, and discharge plan were covered. In AHF patients 
with fluid retention, a prompt diuretic use is encouraged with careful monitoring of 
symptoms, electrolyte imbalance and renal function. Intravenous vasodilators and short-
term intravenous infusion of inotropic agents may improve symptoms in certain condition 
of AHF patients. As well as guideline-directed medical therapy, ultrafiltration, IABP, MCSD, 
37https://e-kcj.org https://doi.org/10.4070/kcj.2018.0349
Korean Guidelines for Acute Heart Failure: Part II
cardiac transplantation, and surgical management can be considered according to the 
indications. A clear and attainable treatment objective must be established, and appropriate 
education must be conducted prior to discharge. A multidisciplinary HF management 
program should be applied to improve outcome especially in high-risk HF patients.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Criteria used to judge the level of evidence and establish the class of recommendation for AHF
Click here to view
Supplementary Table 2
Formulations typically used with each class of recommendation
Click here to view
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